Report overview
Breast cancer is characterized by the malignancy of cells in the tissues of the breast. HER-2 breast cancer is the most common type of breast cancer. The HER-2 protein, present on the surface of normal breast cells, affects the growth of the malignant cells. The uncontrolled synthesis of this protein stimulates the growth and division of malignant cells.
This report aims to provide a comprehensive presentation of the global market for Breast Cancer Monoclonal Antibodies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Breast Cancer Monoclonal Antibodies. This report contains market size and forecasts of Breast Cancer Monoclonal Antibodies in global, including the following market information:
Global Breast Cancer Monoclonal Antibodies Market Revenue, 2018-2023, 2024-2032, ($ millions)
Global Breast Cancer Monoclonal Antibodies Market Sales, 2018-2023, 2024-2032, (K Units)
Global top five Breast Cancer Monoclonal Antibodies companies in 2022 (%)
The global Breast Cancer Monoclonal Antibodies market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The breast cancer monoclonal antibodies (mAbs) market is one of the fastest-growing segments of the?global mAbs market?and has gained major research significance among biotech and pharmaceutical companies due to the presence of high unmet needs in this area.?Antibodies?are increasingly becoming the best choice to treat?cancers, including?breast cancer. The use of?antibody-drug conjugates (ADCs),including radioimmunotherapy and antibody-directed enzyme prodrug therapy, is increasing rapidly.?ADCs?are highly effective cytotoxic drugs linked to mAbs. These drugs have shown to be potent and efficient in treating breast cancer. This has propelled vendors to focus on novel technologies such as Seattle Genetics (SGEN), ImmunoGen (IMGN), and Immunomedics (IMMU). The rising use of these antibodies in drug development increases revenue generation in the breast cancer mAbs market, contributing to market growth.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Breast Cancer Monoclonal Antibodies manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Breast Cancer Monoclonal Antibodies Market, by Type, 2018-2023, 2024-2032 ($ Millions) & (K Units)
Global Breast Cancer Monoclonal Antibodies Market Segment Percentages, by Type, 2022 (%)
Naked MAbs
Conjugated MAbs
Global Breast Cancer Monoclonal Antibodies Market, by Application, 2018-2023, 2024-2032 ($ Millions) & (K Units)
Global Breast Cancer Monoclonal Antibodies Market Segment Percentages, by Application, 2022 (%)
Hospitals
Retail Pharmacies
Others
Global Breast Cancer Monoclonal Antibodies Market, By Region and Country, 2018-2023, 2024-2032 ($ Millions) & (K Units)
Global Breast Cancer Monoclonal Antibodies Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Breast Cancer Monoclonal Antibodies revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Breast Cancer Monoclonal Antibodies revenues share in global market, 2022 (%)
Key companies Breast Cancer Monoclonal Antibodies sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Breast Cancer Monoclonal Antibodies sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Amgen
Roche
Mylan
Array BioPharma
Biocad
Boehringer Ingelheim
Bristol-Myers Squibb
Celldex Therapeutics
Celltrion
Daiichi Sankyo
GlaxoSmithKline
Immunomedics
MacroGenics
Merck
Novartis
Oncothyreon
Pfizer
Puma Biotechnology
Seattle Genetics
Sun Pharmaceutical Industries
Synta Pharmaceuticals
Teva Pharmaceuticals
Outline of Major Chapters:
Chapter 1: Introduces the definition of Breast Cancer Monoclonal Antibodies, market overview.
Chapter 2: Global Breast Cancer Monoclonal Antibodies market size in revenue and volume.
Chapter 3: Detailed analysis of Breast Cancer Monoclonal Antibodies manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Breast Cancer Monoclonal Antibodies in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Breast Cancer Monoclonal Antibodies capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
